
AI-generated summary
As an important trade platform in China, the Canton Fair has seen an increase in the proportion of high-end medical equipment displayed in recent years. China's medical device industry is undergoing a transformation from import dependence to independent research and development.
China News Service, Guangzhou, November 1 (Reporter Cai Minjie) At the booth of the 140th Canton Fair, a peanut-sized smart capsule gastroscope attracted the attention of overseas buyers. The subject only needs to swallow this capsule, and with the help of the accompanying recorder and mobile app, clear images of the stomach will be transmitted back to the screen in real time, intuitively showing the gastric screening process.
Angolan buyer Pedro Pissarra is from a local medical institution. In an interview with a reporter from China News Service on November 1, he said that this trip focused on inspecting portable endoscopes, paying attention to technical parameters and equipment performance. "After on-site experience, I felt the excellent quality of Chinese equipment and planned to carry out product trials in primary medical institutions."
Liu Sizhe, assistant to the chairman of Guangzhou Side Medical Technology Co., Ltd., said that the product has been commercially sold in the mainland and Hong Kong, and plans to extend it from a single examination device to a comprehensive health management service covering dietary guidance and healthy lifestyle intervention to enhance product competitiveness.
At the Canton Fair booth, a laparoscopic surgical robot demonstrated simulated suturing. The operator controls the robotic arm through the open console to complete actions such as sewing and knotting, attracting the attention of buyers from Russia, Italy and other countries.
"The products have a strong sense of technology, and they should be polished through research and development." British buyer Atif N Ishaq believes that products with reliable technology, suitable for long-term use, and priced within the affordable range of the public have broad space in the British market.
Li Hanying, corporate representative of Harbin Sizherui Intelligent Medical Equipment Co., Ltd., said that this fully self-developed endoscopic surgical robot can assist doctors in performing difficult and precise surgical operations. Since this year, it has expanded its business in Europe, Africa and other regions, and provided operational training and technical support to local doctors through overseas partners and professional training systems.
"Different overseas markets show differentiated needs. Some European markets pay more attention to product technical performance and supply chain stability, while markets such as Southeast Asia pay higher attention to equipment procurement costs, operating experience and after-sales service." Li Hanying said that the rapid development of China's high-end medical equipment not only benefits from a relatively complete manufacturing industry chain, but also cannot be separated from the in-depth cooperation between enterprises and front-line clinicians, which can optimize operational details and better meet the actual clinical needs.
"In the early years, most high-end products such as laparoscopes, surgical instruments, and medical consumables relied on imports. Today, a batch of Chinese-made medical equipment has achieved local independent research and development and full-link iterative upgrades." Tan Minghua, president of Guangzhou Fosun Chancheng Hospital, said that for example, Chinese companies have achieved technological breakthroughs in implantable devices such as stents for some aortic dissections, which will benefit patients at home and abroad.
Tan Minghua said that the willingness of overseas patients to come to China for medical treatment is a recognition of China’s medical soft and hard capabilities and also creates opportunities for Chinese medical devices to go overseas.

S&P Global Ratings lowered the outlook on Meta's credit rating from "stable" to "negative", mainly due to the surge in AI infrastructure capital expenditures and significant uncertainty in free cash flow. Although Meta's stock price fell into a technical bear market, some non-tech companies such as Santander and Novartis said that AI investments have begun to pay off.

The People's Bank of China launched the non-bank large-amount redemption swap facility in the bond market to cope with redemption pressure under extreme market fluctuations and prevent a vicious cycle. Officials emphasized that this move is not a disguised form of capital preservation for financial products, but rather a rescue plan without covering up the bottom line, aiming to maintain market stability.

South Korea's exports in October increased by 93.7% year-on-year to US$115.28 billion, the largest increase since 1974. Mainly driven by strong demand for AI-related semiconductors and servers, exports to China and the United States have grown significantly. The Ministry of Trade, Industry and Energy of South Korea predicts that the full-year export volume is expected to exceed the US$1 trillion milestone in November.

The results of the U.S. midterm elections will affect AI industry review, clean energy and defense policies, which will in turn affect the market performance of Asian AI concept stocks such as Taiwan, South Korea and Japan. Investors are worried that policy uncertainty may trigger a pullback in technology stocks.

The China Federation of Logistics and Purchasing released the 2026 Bulk Commodity Price Index Report. It is expected that the average index for the whole year will be 132.1 points, a year-on-year increase of 17.6%. Despite the global economic downturn and geopolitical challenges, China's commodity market still shows strong resilience, with non-ferrous metals, chemicals and energy prices rising significantly.

As of now, 614 companies on the Science and Technology Innovation Board have completed the disclosure of their third quarterly reports for 2026, achieving a total operating income of 1,514.892 billion yuan, a year-on-year increase of 41.88%; a net profit of 223.52 billion yuan, a year-on-year increase of 474.56%. The main business has made outstanding contributions to profit growth, with R&D investment reaching 147.111 billion yuan.